Depomed (DEPO) & Its Rivals Head to Head Survey

Depomed (NASDAQ: DEPO) is one of 496 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its rivals? We will compare Depomed to similar businesses based on the strength of its analyst recommendations, profitability, earnings, institutional ownership, valuation, risk and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Depomed and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Depomed 0 5 2 0 2.29
Depomed Competitors 3072 9318 22337 660 2.58

Depomed presently has a consensus target price of $8.00, indicating a potential upside of 15.44%. As a group, “Pharmaceutical preparations” companies have a potential upside of 37.65%. Given Depomed’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Depomed has less favorable growth aspects than its rivals.

Insider and Institutional Ownership

97.1% of Depomed shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 2.3% of Depomed shares are owned by company insiders. Comparatively, 15.5% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk & Volatility

Depomed has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Depomed’s rivals have a beta of 1.10, suggesting that their average share price is 10% more volatile than the S&P 500.

Earnings and Valuation

This table compares Depomed and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Depomed $380.72 million -$102.49 million -5.50
Depomed Competitors $2.01 billion $135.76 million -3.49

Depomed’s rivals have higher revenue and earnings than Depomed. Depomed is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.


This table compares Depomed and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Depomed -10.02% -15.74% -2.95%
Depomed Competitors -2,976.15% -160.93% -30.80%


Depomed rivals beat Depomed on 8 of the 13 factors compared.

Depomed Company Profile

Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is headquartered in Newark, California.

Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit